Dimitri is a global leader with extensive pharmaceutical industry background, and more than 25 years of international work experience in the US, Europe, Japan, and the Middle East. Recognized as an innovative and organizational change leader who understands market dynamics and the importance of building effective win-win working relationships, Dimitri makes bold bets on the future.
As Chief Executive Officer of Saudi Chemical Pharma, Dimitri has full oversight and accountability for the strategy and performance of the 4 legal entities under the Pharma sector umbrella: SITCO, AJA Pharma, CCCI and CSC.
Prior to joining Saudi Chemical in September ’23, Dimitri spend 15 years with Eli Lilly & Company in a variety of roles around the world. Eli Lilly and Company is an American pharmaceutical company with over 33,000 employees, and is the largest pharmaceutical company in the world by market capitalization.
As President & General Manager of Eli Lilly Saudi Arabia Ltd, Dimitri had full accountability for delivering the regional enterprise growth and transformation agenda across Diabetes, Immunology, Oncology, and Pain Therapeutic Areas. In 2021, Eli Lilly became the first pharmaceutical company to obtain the Regional Headquarter (RHQ) license, placing Riyadh at the center of healthcare in the region.
Prior to relocating to Saudi Arabia in 2018, Dimitri was accountable for Strategy & Operations of Lilly USA Diabetes, the single largest Eli Lilly business entity, with revenue in excess of $5Bn.
Before his transfer to Eli Lilly USA, Dimitri spend 8 years with Lilly in Japan, where he led the introduction and acceleration of new and existing innovative brands, as well as the digital transformation of the 2nd largest Lilly affiliate.
A dual Greek-Belgian citizen and a graduate from NU in Michigan (USA), Dimitri calls Riyadh home, is fully integrated into Saudi society, and is committed to the long-term success of the Kingdom.
